A critical analysis of the 'longevity clinic' phenomenon: serious prevention and offerings with limited evidence coexist. The challenge is separating signal from noise.
The Washington Post investigates the longevity medicine boom — from biohacking expos to high-end clinics — finding that commercial fervor has outpaced both scientific evidence and federal regulation.
A Cell Stem Cell study shows that correcting lysosomal dysfunction in aged mouse blood stem cells restores their regenerative capacity eightfold. Significant, but not a clinic treatment yet.
An editorial in Aging by its Editor-in-Chief reviews the rapid rise of longevity clinics worldwide, highlighting both their potential for data-driven innovation and the serious risks of cost, standardization gaps, and scientific disconnect.